FGF21 and Cardiac Physiopathology

Frontiers in Endocrinology

Volumn 6, Issue , 2015, Pages

  Planavila, Anna ^a,b   Redondo Angulo, Ibon ^a,b   Villarroya, Francesc ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

cardiac hypertrophy; cardiac pathology; oxidative stress; PGC1alpha; sirtuins

Indexed keywords

EID: 84955464951     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00133     Document Type: Review

References (59)

1. Badman MK Pissios P Kennedy AR Koukos G Flier JS Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab (2007) 5:426–37.10.1016/j.cmet.2007.05.00217550778
2. Galman C Lundasen T Kharitonenkov A Bina HA Eriksson M Hafstrom I et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab (2008) 8:169–74.10.1016/j.cmet.2008.06.01418680716
3. Inagaki T Dutchak P Zhao G Ding X Gautron L Parameswara V et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 5:415–25.10.1016/j.cmet.2007.05.00317550777
4. Muise ES Azzolina B Kuo DW El-Sherbeini M Tan Y Yuan X et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol (2008) 74:403–12.10.1124/mol.108.04482618467542
5. Izumiya Y Bina HA Ouchi N Akasaki Y Kharitonenkov A Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett (2008) 582:3805–10.10.1016/j.febslet.2008.10.02118948104
6. Hondares E Iglesias R Giralt A Gonzalez FJ Giralt M Mampel T et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 286:12983–90.10.1074/jbc.M110.21588921317437
7. Kharitonenkov A Shiyanova TL Koester A Ford AM Micanovic R Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 115:1627–35.10.1172/JCI2360615902306
8. Hondares E Rosell M Gonzalez FJ Giralt M Iglesias R Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 11:206–12.10.1016/j.cmet.2010.02.00120197053
9. Fisher FM Kleiner S Douris N Fox EC Mepani RJ Verdeguer F et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 26:271–81.10.1101/gad.177857.11122302939
10. Kharitonenkov A Dunbar JD Bina HA Bright S Moyers JS Zhang C et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol (2008) 215:1–7.10.1002/jcp.2135718064602
11. Kurosu H Choi M Ogawa Y Dickson AS Goetz R Eliseenkova AV et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 282:26687–95.10.1074/jbc.M70416520017623664
12. Fon TK Bookout AL Ding X Kurosu H John GB Wang L et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 24:2050–64.10.1210/me.2010-014220667984
13. Planavila A Redondo I Hondares E Vinciguerra M Munts C Iglesias R et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun (2013) 4:2019.10.1038/ncomms301923771152
14. Planavila A Redondo-Angulo I Ribas F Garrabou G Casademont J Giralt M et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res (2015) 106:19–31.10.1093/cvr/cvu263
15. Liu SQ Roberts D Kharitonenkov A Zhang B Hanson SM Li YC et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep (2013) 3:2767.10.1038/srep0276724067542
16. Joki Y Ohashi K Yuasa D Shibata R Ito M Matsuo K et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun (2015) 459:124–30.10.1016/j.bbrc.2015.02.08125712519
17. Aubert G Vega RB Kelly DP. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta (2013) 1833:840–7.10.1016/j.bbamcr.2012.08.01522964268
18. Lehman JJ Kelly DP. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol (2002) 29:339–45.10.1046/j.1440-1681.2002.03655.x11985547
19. Schilling J Lai L Sambandam N Dey CE Leone TC Kelly DP. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor {gamma} coactivator-1 signaling. Circ Heart Fail (2011) 4:474–82.10.1161/CIRCHEARTFAILURE.110.95983321558447
20. Alvarez-Guardia D Palomer X Coll T Davidson MM Chan TO Feldman AM et al. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res (2010) 87:449–58.10.1093/cvr/cvq08020211864
21. Stachowiak EK Fang X Myers J Dunham S Stachowiak MK. cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J Neurochem (2003) 84:1296–312.10.1046/j.1471-4159.2003.01624.x12614330
22. Ventura-Clapier R Garnier A Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res (2008) 79:208–17.10.1093/cvr/cvn09818430751
23. Eisele PS Salatino S Sobek J Hottiger MO Handschin C. The PGC-1 coactivators repress the transcriptional activity of NF-kappaB in skeletal muscle cells. J Biol Chem (2013) 288:2246–60.10.1074/jbc.M112.37525323223635
24. Patel V Adya R Chen J Ramanjaneya M Bari MF Bhudia SK et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One (2014) 9:e87102.10.1371/journal.pone.008710224498293
25. Brahma MK Adam RC Pollak NM Jaeger D Zierler KA Poecher N et al. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res (2014) 55:2229–41.10.1194/jlr.M04478425176985
26. Gaich G Chien JY Fu H Glass LC Deeg MA Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 18:333–40.10.1016/j.cmet.2013.08.00524011069
27. Fisher FM Chui PC Antonellis PJ Bina HA Kharitonenkov A Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes (2010) 59:2781–9.10.2337/db10-019320682689
28. Villarroya J Flachs P Redondo-Angulo I Giralt M Medrikova D Villarroya F et al. Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids. Lipids (2014) 49:1081–9.10.1007/s11745-014-3948-x25204579
29. Gallego-Escuredo JM Gomez-Ambrosi J Catalan V Domingo P Giralt M Fruhbeck G et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) (2014) 39:121–9.10.1038/ijo.2014.7624813368
30. Diaz-Delfin J Hondares E Iglesias R Giralt M Caelles C Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology (2012) 153:4238–45.10.1210/en.2012-119322778214
31. Yan X Chen J Zhang C Zhou S Zhang Z Chen J et al. FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med (2015) 19:1557–68.10.1111/jcmm.1253025823710
32. Zhang C Huang Z Gu J Yan X Lu X Zhou S et al. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia (2015) 58:1937–48.10.1007/s00125-015-3630-826040473
33. Liu SQ Wu YH. Liver cell-mediated alleviation of acute ischemic myocardial injury. Front Biosci (Elite Ed) (2010) 2:711–24.10.2741/e13120036915
34. Liu SQ Tefft BJ Roberts DT Zhang LQ Ren Y Li YC et al. Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol (2012) 303:H1446–58.10.1152/ajpheart.00362.201223064833
35. Purushotham A Schug TT Xu Q Surapureddi S Guo X Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab (2009) 9:327–38.10.1016/j.cmet.2009.02.00619356714
36. Kim KH Jeong YT Oh H Kim SH Cho JM Kim YN et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med (2013) 19:83–92.10.1038/nm.301423202295
37. Ribas F Villarroya J Hondares E Giralt M Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J (2014) 463:191–9.10.1042/BJ2014040325055037
38. Hojman P Pedersen M Nielsen AR Krogh-Madsen R Yfanti C Akerstrom T et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes (2009) 58:2797–801.10.2337/db09-071319720803
39. Tyynismaa H Carroll CJ Raimundo N Ahola-Erkkila S Wenz T Ruhanen H et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet (2010) 19:3948–58.10.1093/hmg/ddq31020656789
40. Suomalainen A Elo JM Pietilainen KH Hakonen AH Sevastianova K Korpela M et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol (2011) 10:806–18.10.1016/S1474-4422(11)70155-721820356
41. Dogan SA Pujol C Maiti P Kukat A Wang S Hermans S et al. Tissue-specific loss of DARS2 activates stress responses independently of respiratory chain deficiency in the heart. Cell Metab (2014) 19:458–69.10.1016/j.cmet.2014.02.00424606902
42. Di LF Itoh N. Cardiac Fgf21 synthesis and release: an autocrine loop for boosting up antioxidant defenses in failing hearts. Cardiovasc Res (2015) 106:1–3.10.1093/cvr/cvv050
43. Eghbali M Deva R Alioua A Minosyan TY Ruan H Wang Y et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res (2005) 96:1208–16.10.1161/01.RES.0000170652.71414.1615905459
44. Cui Y Giesy SL Hassan M Davis K Zhao S Boisclair YR. Hepatic FGF21 production is increased in late pregnancy in the mouse. Am J Physiol Regul Integr Comp Physiol (2014) 307:R290–8.10.1152/ajpregu.00554.201324898837
45. Redondo-Angulo I Planavila A Giralt M Villarroya F. Involvement of fibroblast growth factor-21 in gestation-induced cardiac hypertrophy. Eur Heart J (2014) 35(Suppl 1):554–5.10.1093/eurheartj/ehu324
46. Markan KR Naber MC Ameka MK Anderegg MD Mangelsdorf DJ Kliewer SA et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes (2014) 63:4057–63.10.2337/db14-059525008183
47. Zhang X Yeung DC Karpisek M Stejskal D Zhou ZG Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes (2008) 57:1246–53.10.2337/db07-147618252893
48. Semba RD Crasto C Strait J Sun K Schaumberg DA Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens (2013) 27:397–9.10.1038/jhh.2012.52
49. Chow WS Xu A Woo YC Tso AW Cheung SC Fong CH et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2013) 33:2454–9.10.1161/ATVBAHA.113.30159923887638
50. Lin Z Wu Z Yin X Liu Y Yan X Lin S et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One (2010) 5:e15534.10.1371/journal.pone.001553421206918
51. An SY Lee MS Yi SA Ha ES Han SJ Kim HJ et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract (2012) 96:196–203.10.1016/j.diabres.2012.01.00422293928
52. Ong KL Januszewski AS O’Connell R Jenkins AJ Xu A Sullivan DR et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the fenofibrate intervention and event lowering in diabetes study. Diabetologia (2015) 58:464–73.10.1007/s00125-014-3458-725425220
53. Han X Chen C Cheng G Xie C Yang M Shou X et al. Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients. Cytokine (2015) 73:176–80.10.1016/j.cyto.2015.02.01925766411
54. Zhang W Chu S Ding W Wang F. Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One (2015) 10:e0129791.10.1371/journal.pone.012979126091256
55. Fredj S Bescond J Louault C Potreau D. Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J Cell Physiol (2005) 202:891–9.10.1002/jcp.2019715389635
56. Gnecchi M He H Liang OD Melo LG Morello F Mu H et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med (2005) 11:367–8.10.1038/nm0405-367
57. Doroudgar S Glembotski CC. The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Trends Mol Med (2011) 17:207–14.10.1016/j.molmed.2010.12.00321277256
58. Frost RJ Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation (2007) 116:1768–75.10.1161/CIRCULATIONAHA.107.69646817909105
59. Stastna M Chimenti I Marban E Van Eyk JE. Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics (2010) 10:245–53.10.1002/pmic.20090051520014349